The evolving ecosystem in the life science and biotechnology sector creates new challenges for companies throughout all stages of their lifecycle. With those new challenges come new opportunities.
Please join us for an informative program series where community experts will share valuable information and insights on how to navigate the landscape and seize opportunities to position yourself for success.
Michael Brooder, National Life Science & Biotech Services Leader, Marcum LLP/p>
Impact of the Pandemic on the Life Science and Biotech Industry and the Future Outlook
As the Life Sciences landscape continually changes during these unprecedented times, many are faced with a wealth of economic uncertainties. Join our panel of industry leaders as they dive into some of the key issues and questions facing the industry today.
In this interactive discussion we will explore:
- The impact of COVID around R&D in organizations
- Impact in pipeline, timelines, pivots, etc.
- Hiring challenges, onboarding and supervision in the virtual era, shifts in types of talents being pursued
- What the future impact might look like and what lasting changes to expect in pharma
Mostafa Analoui – Executive Director, Venture Development & Technology Incubation Program (TIP)
Carine Boustany – SVP, US Development Site Head and Global Head of Development Sciences at Boehringer Ingelheim
Sean Cassidy – Chief Financial Officer, Arvinas
Join our panel of key professionals in accounting, advisory, legal and venture capital as they provide insight into what the existing and emerging “go public” strategies look like in today’s market. We will discuss emerging and existing business exit strategies, options you may consider for your company, pros and cons, and how to plan your strategy for your life science or biotech organization.
Michael Brooder, National Technology & Life Sciences Services Leader, Marcum LLP
Alexandria Kane, Partner, White and Williams LLP
Timothy M. Shannon, M.D., General Partner, Canaan Partners
Shauna Watson, Managing Director, Head of Public Company Readiness, Accordion
Building Momentum in Connecticut’s Bioscience Industry
What the state of Connecticut is doing to support business formation, growth and talent development.
Josh Geballe, Chief Operating Officer to Governor Ned Lamont
Josh Geballe is currently serving as Chief Operating Officer to Governor Ned Lamont, responsible for the executive branch operations of all 25 state agencies and over 30,000 employees providing essential services to the state of Connecticut. He was appointed to the role on February 27, 2020, adding to his responsibilities as Commissioner for the Department of Administrative Services, the agency responsible for the business functions of state government including technology, human resources, procurement, real estate and more, where he has served since January 2019.
Prior to joining the Lamont Administration Josh spent 18 years in the private sector leading, investing in and advising technology businesses. Most recently he was the Vice President and General Manager of Digital Science at Thermo Fisher Scientific (NYSE: TMO), a multi-national scientific technology company. Josh joined Thermo Fisher when it acquired his software company, Core Informatics, LLC, in March 2017. He joined Core Informatics as CEO in 2013 after 11 years at IBM where he held multiple international executive roles spanning general management, finance and strategy.
Josh holds an MBA from the Yale School of Management and BA from Yale University, and lives in Guilford, CT with his wife and two children.
Mostafa Analoui, Ph.D., is Executive Director of Venture Development and Technology Incubation Program (TIP) at UConn. Previously, he was Head of Healthcare and Life Sciences at Livingston Securities (New York, NY) with investment focus in private and public companies in biotech, medtech and healthcare services. Prior to that, he was the Senior Director at Pfizer Global Research and Development. Dr. Analoui is actively involved in investment, management and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies.
While at Pfizer, he was the Site Head for Global Clinical Technology in Groton and New London, a division focusing on emerging technologies for development and validation of biomarkers and diagnostics for drug development. Prior to joining Pfizer, Dr. Analoui was the Director of Oral and Maxillofacial Imaging Research, Associate Professor of Radiology at Indiana University, and Associate Professor of Biomedical Engineering and Electrical & Comp Engineering at Purdue University. He was also President and CEO of Therametric Technology Inc. He has received his Ph.D. from Purdue University, followed by Post-Doctoral Fellowship at IBM TJ Watson Research Center in NY.
In addition to industry leadership in biomedical and technology fields, he consults and lectures in US, Europe and Asia. He has also served on various scientific, regulatory, and business advisory committees and boards, including NIH, NSF, PhRMA, NASA, and OECD. Dr. Analoui has authored over 130 publications, including journal articles, a book and book chapters and technical reports. Dr. Analoui is currently Adjust Professor at University of Connecticut (Storrs/Farmington, CT), Brown University (Providence, RI), and Northeastern University (Boston, MA). He is also senior member of IEEE, SPIE, and RSNA.
He was Chairman of the Board of VirtualScopics (Nasdaq: VSCP) and currently serves as Chairman of the Board member of Cyclica (Chairman), Connecticut Innovations, and NanoBusiness Commercialization Association.
Carine Boustany is the US Development Site head and global head of Development Sciences at Boehringer Ingelheim. Previously, Carine led the department of Cardiometabolic Diseases Research in the US where she was responsible for leading a team of scientists focused on delivering innovative therapies to improve the lives of patients suffering from cardiometabolic diseases, with a particular focus on NASH and CKD. Under her leadership, the team built a portfolio of first in class molecules, several of which are currently in clinical testing.
Prior to joining Boehringer Ingelheim in 2011, Carine was a researcher at Pfizer where she led project teams in diabetes and diabetic nephropathy. Notably, Carine led the biology team that discovered and advanced to the clinic ertugliflozin, a novel anti-diabetic registered as Steglatro. Carine was also an Assistant Professor at the Lebanese International University (Beirut, Lebanon) and at the Holy Spirit University (Kaslik, Lebanon) prior to joining Pfizer. Consistent with her experience spanning preclinical to clinical research, Carine’s education includes a PharmD degree from Saint-Joseph University (Beirut, Lebanon), followed by a PhD in Pharmaceutical Sciences from the College of Pharmacy at the University of Kentucky (Lexington, Kentucky), and a post-doctoral fellowship at the University of Kentucky.
Carine also serves as a board member of the IQ consortium, as well as BioCT, which aims to position Connecticut as a center of biotechnology and innovation.
Mr. Cassidy is the Chief Financial Officer of Arvinas. He has over 20 years of experience in the life sciences industry, including serving as Chief Financial Officer of Axerion Therapeutics, a preclinical biotechnology company developing therapies for neurological diseases and injuries; Chief Financial Officer of CuraGen Corporation (NASDAQ: CRGN), a clinical stage biopharmaceutical company; and Director and Controller of 454 Life Sciences Corporation, a life sciences company that developed and commercialized next generation DNA sequencing instruments and reagents.
Earlier in his career, Mr. Cassidy served at Deloitte, one of the big four public accounting firms with a broad base of clients in the healthcare space. Mr. Cassidy is currently a board member of the Friends of Yale New Haven Children’s Hospital, a nonprofit organization that helps improve the health and well-being of pediatric patients and their families.
Mr. Cassidy holds an M.B.A. and B.S. from the University of Connecticut and is a Certified Public Accountant in the State of Connecticut.
Alexandria Kane concentrates her practice in corporate law, securities and mergers and acquisitions. She represents and advises investors and public and private companies in general corporate governance, business formations, capital transactions, mergers and acquisitions and securities law compliance.
Alexandria regularly serves as outside general counsel to corporate clients, providing ongoing legal analysis of corporate risks and opportunities, and drafting and negotiating stock purchase agreements, shareholder agreements, consulting agreements, employment agreements, joint venture agreements and loan agreements. She also has extensive experience in preparing and advising clients concerning required securities filings and private placements of securities.
Timothy M. Shannon
Tim is a General Partner at Canaan Partners. While at Canaan, Tim has served in a number of executive roles at biotechnology companies, including the founding CEO of Arvinas, Inc. He currently serves as the founding Executive Chair of Halda Therapeutics. Prior to Canaan, he served as Executive Vice President of R&D and Chief Medical Officer of CuraGen Corporation and Senior Vice President of Global Medical Development, Bayer Healthcare LLC. Prior to his career in industry, Dr. Shannon was an Assistant Professor in the Pulmonary and Critical Care Division at Yale University School of Medicine. Tim serves on several pubic boards, including RallyBio, and is chairman of the Boards of Directors of Arvinas, Inc. and of Ideaya Biosciences, Inc., He is a founding investor and sits on the board of private companies Vivace and Halda. He was formerly a lead investor and served as a board member of Civtas Therapeutics, NextCure Inc., CytomX Therapeutics, Inc., and served on the board Celldex Therapeutics after its merger with CuraGen.
Tim earned a B.A. in chemistry from Amherst College and an M.D. from the University of Connecticut.
Shauna, CPA, is a Managing Director with nearly three decades of experience spanning a variety of sectors including consulting, energy & aerospace, and defense. She is a subject matter expert in US GAAP, IFRS, SOX, and SEC Regulations. Shauna has helped companies implement new accounting standards like leases and revenue recognition. She has also worked on complicated deal and accounting structures often seen in M&A, carve-outs, IPOs, and GAAP conversions.
At RGP, a global consulting company, she led the technical accounting practice and developed end-to-end solutions for revenue recognition and lease accounting compliance, achieving triple digit year-over-year growth. She was a recognized and frequent presenter on technical accounting matters.
As Corporate Director of Technical Accounting and Policy at Northrop Grumman, a Fortune 100 Aerospace & Defense company, she evaluated and concluded on complex business transactions, drafted comment letters for submission to the SEC, FASB, IASB, and PCAOB, and led the ongoing IFRS implementation efforts. From that she transitioned into the Corporate Director of FP&A role, responsible for monthly planning and analysis, what-if scenarios for potential executive actions, the long range strategic plan, and reporting to the Board of Directors.
During her 11 years at PricewaterhouseCoopers, she was a Senior Manager in Audit and Advisory Services, and spent several years in PwC’s Global Capital Markets Group in Germany. There she consulted on US GAAP and SEC regulations for capital raising and M&A activities.
Shauna graduated with the highest honors from Montana State University with a B.S. in Accounting, received her MBA from UCLA’s Anderson School of Business, and is a Certified Public Accountant.
Certified Financial Services
Certified Financial Services is a protection first wealth management firm. D.Cristi Stroud and Tommy Vorio are financial advisors in the business exit planning division. Our interdisciplinary strategic approach will help your business to protect against loss, accelerate value by recruiting, rewarding, and retaining top talent, and create transferable value that allows business owners to exit on their terms at the highest possible value.